Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Combinatorial Treatment Strategy of 177 Lu-PSMA-617 and Docetaxel Chemotherapy in Highly PSMA- and FDG-Avid (Pro-PET Score 3) Metastatic Castration-Resistant Prostate Cancer While Considering Pre-taxane PRLT

Abstract 177 Lu-PSMA-617 targeted radioligand therapy (RLT) received U.S. Food and Drug Administration approval in 2022 for metastatic castration-resistant prostate cancer (mCRPC) patients progressing after androgen receptor pathway inhibitors and taxane chemotherapy. Despite its efficacy, response rates vary, promptin...

Amal Paul, Keerti Sitani, Sandip Basu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.